mirage

Peripheral brain-derived neurotrophic factor levels in alzheimer's disease and mild cognitive impairment: A comprehensive systematic review and meta-analysis

ABACUS/Manakin Repository

Show simple item record

dc.contributor.author Kim, Bo Yi
dc.contributor.author Lee, Seon Heui
dc.contributor.author Graham, Petra L.
dc.contributor.author Angelucci, Francesco
dc.contributor.author Lucía Mulas, Alejandro
dc.contributor.author Pareja Galeano, Helios
dc.contributor.author Leyhe, Thomas
dc.contributor.author Turana, Yuda
dc.contributor.author Lee, I. Re
dc.contributor.author Yoon, Ji Hye
dc.contributor.author Shin, Jae Il
dc.date.accessioned 2016-11-22T16:17:08Z
dc.date.available 2016-11-22T16:17:08Z
dc.date.issued 2017
dc.identifier.citation Kim, B. Y., Lee, S. H., Graham, P. L., Angelucci, F., Lucía, A., Pareja-Galeano, H., ... & Shin, J. I. (2017). Peripheral brain-derived neurotrophic factor levels in alzheimer’s disease and mild cognitive impairment: A comprehensive systematic review and meta-analysis. Molecular Neurobiology, 54(9), 7297-7311. spa
dc.identifier.issn 08937648
dc.identifier.issn 15591182
dc.identifier.uri http://hdl.handle.net/11268/5991
dc.description.abstract Alzheimer's disease (AD) is becoming a growing global problem, and there is an urgent need to identify reliable blood biomarkers of the risk and progression of this condition. A potential candidate is the brain-derived neurotrophic factor (BDNF), which modulates major trophic effects in the brain. However, findings are apparently inconsistent regarding peripheral blood BDNF levels in AD patients vs. healthy people. We thus performed a systematic review and meta-analysis of the studies that have examined peripheral BDNF levels in patients with AD or mild cognitive impairment (MCI) and healthy controls. We searched articles through PubMed, EMBASE, and hand searching. Over a total pool of 2061 potential articles, 26 met all inclusion criteria (including a total of 1584 AD patients, 556 MCI patients, and 1294 controls). A meta-analysis of BDNF levels between early AD and controls showed statistically significantly higher levels (SMD [95 % CI]: 0.72 [0.31, 1.13]) with no heterogeneity. AD patients with a low (<20) mini-mental state examination (MMSE) score had lower peripheral BDNF levels compared with controls (SMD [95 % CI]: -0.33 [-0.60, -0.05]). However, we found no statistically significant difference in blood (serum/plasma) BDNF levels between all AD patients and controls (standard mean difference, SMD [95 % CI]: -0.16 [-0.4, 0.07]), and there was heterogeneity among studies (P < 0.0001, I 2 = 85.8 %). There were no differences in blood BDNF levels among AD or MCI patients vs. controls by subgroup analyses according to age, sex, and drug use. In conclusion, this meta-analysis shows that peripheral blood BDNF levels seem to be increased in early AD and decreased in AD patients with low MMSE scores respectively compared with their age- and sex-matched healthy referents. At present, however, this could not be concluded from individual studies. spa
dc.description.sponsorship SIN FINANCIACIÓN spa
dc.language.iso eng spa
dc.title Peripheral brain-derived neurotrophic factor levels in alzheimer's disease and mild cognitive impairment: A comprehensive systematic review and meta-analysis spa
dc.type article spa
dc.description.impact 5.076 JCR (2017) Q1, 44/261 Neurosciences spa
dc.identifier.doi 10.1007/s12035-016-0192-9
dc.rights.accessRights openAccess spa
dc.subject.uem Alzheimer, Enfermedad de spa
dc.subject.uem Cerebro - Envejecimiento spa
dc.subject.unesco Cerebro spa
dc.subject.unesco Envejecimiento spa
dc.description.filiation UEM spa
dc.peerreviewed Si spa


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record